top of page
The Professional Network for Healthcare Experts
Sudarshan Pharma approves acquisition of 9.5% stake in MedTherapy Biotechnology
Sudarshan Pharma has approved the acquisition of a 9.5% stake in US-based MedTherapy Biotechnology, expanding its exposure to oncology cell and gene therapy.
nuaxia
4 hours ago2 min read
ArsenalBio cuts 99 jobs as it pivots to in vivo CAR-T development
ArsenalBio is cutting 99 jobs as it restructures the company around a strategic shift towards in vivo CAR-T development.
nuaxia
6 days ago1 min read
Bristol Myers Squibb ends $380 million Cellares CAR-T manufacturing partnership
BMS concluded that Cellares’ automated Cell Shuttle platform could not meet the specific requirements for commercial Breyanzi production, prompting Cellares to cut around 100 positions.
nuaxia
Aug 273 min read
bottom of page